^
Association details:
Biomarker:ROS1 fusion
Cancer:Melanoma
Drug:Xalkori (crizotinib) (ALK inhibitor)
Direction:Sensitive
Evidence:
Evidence Level:
Sensitive: A2 - Guideline
New
Source:
Excerpt:
Fusions in ALK and ROS1, more common in lung cancer, occur uncommonly (>1% incidence) across subtypes of melanoma. Fusions in these genes may predispose to clinical activity from inhibitors of these genes (eg, crizotinib and entrecitinib).